Intracameral Bevacizumab as an Adjunct to Trabeculectomy: a 1-Year Prospective, Randomised Study
| العنوان: | Intracameral Bevacizumab as an Adjunct to Trabeculectomy: a 1-Year Prospective, Randomised Study |
|---|---|
| المؤلفون: | Ingeborg Stalmans, Evelien Vandewalle, Steffen Fieuws, Tine Van Bergen, Luís Abegão Pinto, Lieve Moons, Werner Spileers, Leigh Spielberg, Thierry Zeyen |
| المصدر: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação instacron:RCAAP |
| بيانات النشر: | BMJ, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Intraocular pressure, Time Factors, Bevacizumab, genetic structures, Angiogenesis Inhibitors / adverse effects, medicine.medical_treatment, Glaucoma, Antibodies, Monoclonal, Humanized / adverse effects, Angiogenesis Inhibitors, Trabeculectomy, Kaplan-Meier Estimate, Placebo, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Humanized / administration & dosage, Glaucoma, Open-Angle / drug therapy, Cellular and Molecular Neuroscience, Double-Blind Method, medicine, Humans, Prospective Studies, Prospective cohort study, Aged, Angiogenesis Inhibitors / administration & dosage, business.industry, HSAC OFT, Light perception, Middle Aged, medicine.disease, Glaucoma, Open-Angle / surgery, Sensory Systems, eye diseases, Surgery, Clinical trial, Ophthalmology, Chemotherapy, Adjuvant, Anesthesia, Female, sense organs, business, Glaucoma, Open-Angle, medicine.drug |
| الوصف: | Aims: To investigate the efficacy and safety of a single intracameral bevacizumab injection to improve the outcome of trabeculectomy. Methods: A 12-month, prospective, randomised, double-masked, placebo-controlled trial. Patients with medically uncontrolled open-angle glaucoma scheduled for a primary trabeculectomy were recruited and randomised to receive 50 µL of either bevacizumab (1.25 mg) or placebo (balanced salt solution) peroperatively. Absolute success was defined as intraocular pressure (IOP) ≤18 mm Hg and >5 mm Hg with at least 30% reduction from baseline and no loss of light perception. Success through the use of additional medical and/or surgical IOP-lowering treatments was defined as qualified success. Results: 138 patients completed a 12-month follow-up, 69 of whom were in the bevacizumab treated group. IOP at 1 year postoperatively was significantly lower than baseline (placebo: 25.6±9.9 mm Hg vs 11.5±3.9 mm Hg, p |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2d6eaae4904ff0ea8891999059cec2fTest https://hdl.handle.net/10400.17/3807Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....d2d6eaae4904ff0ea8891999059cec2f |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |